Prakhar Agrawal
Stock Analyst at Cantor Fitzgerald
(3.50)
# 836
Out of 5,154 analysts
52
Total ratings
39.58%
Success rate
9.84%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Prakhar Agrawal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MANE Veradermics | Initiates: Overweight | n/a | $48.56 | - | 1 | Mar 2, 2026 | |
| EVMN Evommune | Initiates: Overweight | n/a | $26.50 | - | 1 | Dec 1, 2025 | |
| MDGL Madrigal Pharmaceuticals | Upgrades: Overweight | n/a | $432.83 | - | 5 | Nov 5, 2025 | |
| ATYR aTyr Pharma | Downgrades: Neutral | n/a | $0.82 | - | 2 | Sep 15, 2025 | |
| AVTX Avalo Therapeutics | Initiates: Overweight | n/a | $17.31 | - | 1 | Aug 15, 2025 | |
| GPCR Structure Therapeutics | Reiterates: Overweight | $65 | $57.73 | +12.59% | 13 | Jun 23, 2025 | |
| ORIC ORIC Pharmaceuticals | Reiterates: Overweight | n/a | $13.71 | - | 7 | May 6, 2025 | |
| TVTX Travere Therapeutics | Reiterates: Overweight | n/a | $27.24 | - | 3 | Apr 23, 2025 | |
| ACRS Aclaris Therapeutics | Reiterates: Overweight | n/a | $3.06 | - | 1 | Mar 18, 2025 | |
| KROS Keros Therapeutics | Downgrades: Neutral | n/a | $11.30 | - | 3 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $10 | $4.47 | +123.96% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $18.15 | - | 10 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $24 | $29.27 | -18.00% | 2 | Apr 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | $3.61 | +12,365.37% | 1 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $1.77 | +690.96% | 1 | Mar 3, 2021 |
Veradermics
Mar 2, 2026
Initiates: Overweight
Price Target: n/a
Current: $48.56
Upside: -
Evommune
Dec 1, 2025
Initiates: Overweight
Price Target: n/a
Current: $26.50
Upside: -
Madrigal Pharmaceuticals
Nov 5, 2025
Upgrades: Overweight
Price Target: n/a
Current: $432.83
Upside: -
aTyr Pharma
Sep 15, 2025
Downgrades: Neutral
Price Target: n/a
Current: $0.82
Upside: -
Avalo Therapeutics
Aug 15, 2025
Initiates: Overweight
Price Target: n/a
Current: $17.31
Upside: -
Structure Therapeutics
Jun 23, 2025
Reiterates: Overweight
Price Target: $65
Current: $57.73
Upside: +12.59%
ORIC Pharmaceuticals
May 6, 2025
Reiterates: Overweight
Price Target: n/a
Current: $13.71
Upside: -
Travere Therapeutics
Apr 23, 2025
Reiterates: Overweight
Price Target: n/a
Current: $27.24
Upside: -
Aclaris Therapeutics
Mar 18, 2025
Reiterates: Overweight
Price Target: n/a
Current: $3.06
Upside: -
Keros Therapeutics
Jan 21, 2025
Downgrades: Neutral
Price Target: n/a
Current: $11.30
Upside: -
Dec 17, 2024
Initiates: Overweight
Price Target: $10
Current: $4.47
Upside: +123.96%
Sep 23, 2024
Reiterates: Overweight
Price Target: n/a
Current: $18.15
Upside: -
Apr 17, 2023
Reiterates: Overweight
Price Target: $24
Current: $29.27
Upside: -18.00%
Jul 15, 2022
Assumes: Overweight
Price Target: $450
Current: $3.61
Upside: +12,365.37%
Mar 3, 2021
Initiates: Buy
Price Target: $14
Current: $1.77
Upside: +690.96%